All patients referred to a participating research centre with suspicion of or confirmed endometrial cancer.
Patients with endometrial or epithelial ovarian cancer who following routine clinical guidelines are offered weekly taxane (paclitaxel) treatment. This will often be a third or fourth line treatment, i.e. patients with advanced disease.
Technical possibility to obtain a new tissue biopsy to determine stathmin level in the tumour recurrence.

NCT02543710_inc_T1
Visit
participating research centre
NCT02543710_inc_T2
Mood
suspicion of
NCT02543710_inc_T3
Qualifier
confirmed
NCT02543710_inc_T4
Condition
endometrial cancer
NCT02543710_inc_T5
Scope
suspicion of or confirmed
NCT02543710_inc_T6
Condition
epithelial ovarian cancer
NCT02543710_inc_T7
Condition
ndometrial varian cancer
NCT02543710_inc_T8
Multiplier
weekly
NCT02543710_inc_T9
Drug
taxane
NCT02543710_inc_T10
Drug
paclitaxel
NCT02543710_inc_T11
Procedure
treatment
NCT02543710_inc_T13
Procedure
tissue biopsy
NCT02543710_inc_T14
Mood
Technical possibility to obtain
NCT02543710_inc_T15
Condition
tumour recurrence